Stockreport

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Royalty Pharma plc Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalt [Read more]